FILE PHOTO: A sign marks the headquarters of Moderna Therapeutics, which is developing a vaccine against the coronavirus disease (COVID-19), in Cambridge, Massachusetts, U.S., May 18, 2020. REUTERS/Brian Snyder/File Photo
(Reuters) - Moderna Inc became the second U.S company to release full results from a large study of its experimental vaccine, saying it was 94.1% effective against COVID-19.
It will seek emergency use authorization from the U.S. Food and Drug Administration and conditional approval from the European Union on Monday.
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
